SAVA Cassava Pharma: Market Value to Book Value Ratio
This chart of Cassava Sciences, Inc. (SAVA) price action demonstrates volatility amid rigorous regulatory scrutiny and disputes over data accuracy, where the risk stands at 1.41. Cassava Sciences, Inc. (SAVA) is striving for market dominance through the final trials of simufilam. Simultaneously, the company is developing a comprehensive approach to dementia therapy, leveraging fundamental neurobiology to eradicate the causes of Alzheimer's disease.
Cassava Sciences Inc (SAVA) - metric breakdowns and financial figures
- share price and expert price forecast:
- company stock capitalization data:
- book capitalization data:
- debt and solvency information:
- earnings and valuation multiples indicators:
Comprehensive company analysis:Cassava Sciences, Inc. - SAVA
This ratio compares the market value of the business to its net assets, identifying any overpayment for the company. Values above one indicate a premium for future growth or intangible assets. By analyzing changes in the market-to-book ratio, an investor separates speculative noise from fundamental value. For Cassava Sciences, Inc. (SAVA), this gap reflects market expectations regarding FDA approval of simufilam.
Main competitors
BIIB: Market Capitalization to Book Value Ratio|neurocrine.com (NBIX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|AMLX (Amylyx Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio trevitherapeutics.com (TRVI)|Market Capitalization to Book Value Ratio PRAX|Market Capitalization to Book Value Ratio Anavex (AVXL)|Market Value to Book Value Ratio CeriBell Corp CBLL|Market Capitalization to Book Value Prothena (PRTA)|ALEC - Market Value to Book Value Ratio|Market Capitalization to Book Value annexonbio.com ANNX|OMER: Market Capitalization to Book Value Ratio|Neurogene Inc (NGNE) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio ACIU|Market Value to Book Value Ratio VYGR|Market Capitalization to Book Value Ratio NMRA|Market Capitalization to Book Value Ratio scilexholding.com (SCLX)|Tevogen Bio - Market Cap to Net Assets Ratio|Market Value to Book Value ACOG|CGTX - Market Value to Book Value Ratio|Market Capitalization to Book Value Inhibikase Pharma IKT|ASRT: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Coya Therapeutics|VTGN (VistaGen Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Ovid Rx (OVID) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio ABOS|CRVO - Market-to-Book Ratio|Market Value to Book Value Ratio Alterity Therapeutics Limited ATHE|CLNN: Capitalization to Book Value Ratio|PepGen Corp - Market Capitalization to Book Value Ratio|jupiterneurosciences.com (JUNS) - Market Cap to Net Assets Ratio|RLMD: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Annovis Bio Corporation (ANVS)|Market Value to Book Value Ratio Grace Therapeutics Inc|fireflyneuro.com (AIFF) - Market Capitalization to Book Value|Market Cap to Net Assets Ratio KLTO (Klotho Neurosciences Inc)|NRSN (neurosense-tx.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio RVPH (Reviva Pharmaceuticals Holdings)|Market Capitalization to Book Value MetaVia Inc. (MTVA)|NRXS - Market Value to Book Value Ratio|HSDT (Helius Medical) - Capitalization to Book Value Ratio|PASG: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Neuphoria Therapeutics|Market Cap to Net Assets Ratio NERV|Athira Pharma Corp (ATHA) - Market Capitalization to Book Value|Market Value to Book Value Ratio Addex Therapeutics (ADXN)|Market Capitalization to Book Value alzamend.com|Market Capitalization to Book Value Ratio CYCN (Cyclerion Therapeutics, Inc.)|Market Capitalization to Book Value Ratio Protagenic Therapeutics Inc. PTIX|KTTA: Market Cap to Net Assets Ratio|CRGT: Market Value to Book Value Ratio|ATXI: Market Capitalization to Book Value Ratio|brainstorm-cell.com (BCLI) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Cara Therapeutics|Capitalization to Book Value Ratio CHRO (Chromocell Therapeutics Corp)|Market Capitalization to Book Value Ratio ELYM|ITCI - Market-to-Book Ratio|Longboard Pharmaceuticals - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio marinuspharma.com MRNS|NKGN - Market Value to Book Value Ratio|Market Value to Book Value NRBO (NeuroBo Pharmaceuticals Inc)|Sage Therapeutics, Inc (SAGE) - Market Value to Book Value Ratio|Market-to-Book Ratio Synaptogenix, Inc (SNPX)|TRVN (Trevena, Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Vigil Neuro (VIGL)|Market Capitalization to Book Value Ratio WENA|Market Capitalization to Book Value Ratio Cerevel Therapeutics Inc (CERE)